Spinal Muscular Atrophy Treatment Market By Type (Type 1, Type 2, Others), By Route of Administration (Oral, Parenteral), By End User (Hospitals, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
Description
Spinal Muscular Atrophy Treatment Market By Type (Type 1, Type 2, Others), By Route of Administration (Oral, Parenteral), By End User (Hospitals, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
The global spinal muscular atrophy treatment market was valued at $4.3 billion in 2022, and is projected to reach $8.4 billion by 2032, growing at a CAGR of 6.8% from 2023 to 2032.
Spinal muscular atrophy (SMA) is a genetic disorder that affects the motor neurons, which are the nerve cells responsible for controlling voluntary muscle movements. It is characterized by the progressive degeneration of these motor neurons, leading to muscle weakness and atrophy. The symptoms of SMA can vary widely, but they generally involve muscle weakness and atrophy, difficulty with motor function, respiratory problems, and reduced mobility. The severity of the condition and the rate of disease progression can also vary among individuals.
The most widely used and effective treatment for spinal muscular atrophy is gene replacement therapy. One such therapy is called Onasemnogene abeparvovec (Zolgensma). It involves delivering a functional copy of the SMN1 gene (which is deficient in SMA) to motor neurons using a viral vector. This therapy has shown remarkable success in infants with SMA and has the potential to halt disease progression.
The major factors that drive the growth of the global spinal muscular atrophy treatment market include, increase in prevalence of spinal muscular atrophy. For instance, according to the Centers for disease Control and Prevention (CDC) in March 2023, spinal muscular atrophy (SMA) is a genetic disorder that affects approximately 1 out of every 10,000 people.
As more cases are diagnosed and reported, there is a growing patient population that requires effective treatment options. This increase in prevalence of SMA contributes to the expansion of the market growth. The introduction of disease-modifying therapies, such as Nusinersen and Onasemnogene abeparvovec, has revolutionized the treatment landscape for SMA. These therapies have shown significant clinical benefits and improved the prognosis for individuals with SMA, leading to increased demand for SMA drugs and propels the market growth.
In addition, improved understanding, and awareness of SMA among healthcare professionals and the public, there has been an emphasis on early diagnosis through genetic testing. Early detection allows for timely intervention and treatment initiation, which is driving the demand for SMA therapies. Another market driver is the growing recognition of rare diseases significance, rise in initiatives to raise SMA awareness, and increase in research efforts by market participants to develop effective treatments for SMA. However, high cost of the spinal muscular atrophy treatment limits the adoption of SMA drugs which restrain the market growth.
The global spinal muscular atrophy treatment market is segmented into type, route of administration, distribution channel, and region. By type, the market is categorized into type 1, type 2, and others. By route of administration, the market is bifurcated into oral and parenteral. By end user, the market is classified into hospitals and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).
Major key players that operate in the global spinal muscular atrophy treatment market are Biogen, Beijing Jinlan Gene Technology Co., Ltd., Cytokinetics, F. Hoffmann-La Roche Ltd., Hanugen Theraputics, Ionis Pharmaceuticals, Inc. NMD PHARMA A/S, Novartis AG, Pfizer Inc., and Scholar Rock Holding Corporation. Key players operating in the market have adopted product approval, product launch, and agreement as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the spinal muscular atrophy treatment market analysis from 2022 to 2032 to identify the prevailing spinal muscular atrophy treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the spinal muscular atrophy treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global spinal muscular atrophy treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Type 1
Type 2
Others
By Route of Administration
Oral
Parenteral
By End User
Hospitals
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Latin America
Middle East And Africa
Key Market Players
Beijing Jinlan Gene Technology Co., Ltd.
Biogen
Cytokinetics
F. Hoffmann-La Roche Ltd.
Hanugen Theraputics
Ionis Pharmaceuticals, Inc.
NMD Phrama A/S
Novartis AG
Pfizer Inc.
Scholar Rock Holding Corporation
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
239 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in prevalence of spinal muscular atrophy
- 3.4.1.2. Initiatives by government organizations
- 3.4.1.3. Increase in the demand for drugs for the SMA
- 3.4.2. Restraints
- 3.4.2.1. High cost of SMA drugs
- 3.4.3. Opportunities
- 3.4.3.1. Increase in R&D activities
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Type 1
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Type 2
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- CHAPTER 5: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Oral
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Parenteral
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Others
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- CHAPTER 7: SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Route of Administration
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Type
- 7.2.5.1.3. Market size and forecast, by Route of Administration
- 7.2.5.1.4. Market size and forecast, by End User
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Type
- 7.2.5.2.3. Market size and forecast, by Route of Administration
- 7.2.5.2.4. Market size and forecast, by End User
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Type
- 7.2.5.3.3. Market size and forecast, by Route of Administration
- 7.2.5.3.4. Market size and forecast, by End User
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Route of Administration
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Type
- 7.3.5.1.3. Market size and forecast, by Route of Administration
- 7.3.5.1.4. Market size and forecast, by End User
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Type
- 7.3.5.2.3. Market size and forecast, by Route of Administration
- 7.3.5.2.4. Market size and forecast, by End User
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Type
- 7.3.5.3.3. Market size and forecast, by Route of Administration
- 7.3.5.3.4. Market size and forecast, by End User
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Type
- 7.3.5.4.3. Market size and forecast, by Route of Administration
- 7.3.5.4.4. Market size and forecast, by End User
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Type
- 7.3.5.5.3. Market size and forecast, by Route of Administration
- 7.3.5.5.4. Market size and forecast, by End User
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Type
- 7.3.5.6.3. Market size and forecast, by Route of Administration
- 7.3.5.6.4. Market size and forecast, by End User
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Route of Administration
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Type
- 7.4.5.1.3. Market size and forecast, by Route of Administration
- 7.4.5.1.4. Market size and forecast, by End User
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Type
- 7.4.5.2.3. Market size and forecast, by Route of Administration
- 7.4.5.2.4. Market size and forecast, by End User
- 7.4.5.3. India
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Type
- 7.4.5.3.3. Market size and forecast, by Route of Administration
- 7.4.5.3.4. Market size and forecast, by End User
- 7.4.5.4. Australia
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Type
- 7.4.5.4.3. Market size and forecast, by Route of Administration
- 7.4.5.4.4. Market size and forecast, by End User
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Type
- 7.4.5.5.3. Market size and forecast, by Route of Administration
- 7.4.5.5.4. Market size and forecast, by End User
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Type
- 7.4.5.6.3. Market size and forecast, by Route of Administration
- 7.4.5.6.4. Market size and forecast, by End User
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Route of Administration
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Latin America
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Type
- 7.5.5.1.3. Market size and forecast, by Route of Administration
- 7.5.5.1.4. Market size and forecast, by End User
- 7.5.5.2. Middle East And Africa
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Type
- 7.5.5.2.3. Market size and forecast, by Route of Administration
- 7.5.5.2.4. Market size and forecast, by End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Biogen
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. Cytokinetics
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Hanugen Theraputics
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.4. NMD Phrama A/S
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Key strategic moves and developments
- 9.5. Novartis AG
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. F. Hoffmann-La Roche Ltd.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Pfizer Inc.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Scholar Rock Holding Corporation
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Beijing Jinlan Gene Technology Co., Ltd.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Key strategic moves and developments
- 9.10. Ionis Pharmaceuticals, Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 02. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 1, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 2, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 05. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 06. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 09. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
- TABLE 10. SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 13. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 14. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 15. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 16. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 17. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 18. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 19. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 20. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 21. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 22. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 23. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 24. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 25. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 26. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 27. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 28. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 29. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 30. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 31. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 32. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 33. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 34. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 35. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 36. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 37. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 38. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 39. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 40. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 41. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 42. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 43. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 44. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 45. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 46. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 47. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 48. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 49. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 50. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 51. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 52. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 53. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 54. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 55. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 56. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 57. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 58. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 59. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 60. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 61. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 62. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 63. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 64. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 65. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 66. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 69. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 70. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 71. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 72. LAMEA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 73. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 74. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 75. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 76. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 77. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
- TABLE 78. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 79. BIOGEN: KEY EXECUTIVES
- TABLE 80. BIOGEN: COMPANY SNAPSHOT
- TABLE 81. BIOGEN: PRODUCT SEGMENTS
- TABLE 82. BIOGEN: PRODUCT PORTFOLIO
- TABLE 83. CYTOKINETICS: KEY EXECUTIVES
- TABLE 84. CYTOKINETICS: COMPANY SNAPSHOT
- TABLE 85. CYTOKINETICS: PRODUCT SEGMENTS
- TABLE 86. CYTOKINETICS: PRODUCT PORTFOLIO
- TABLE 87. HANUGEN THERAPUTICS: KEY EXECUTIVES
- TABLE 88. HANUGEN THERAPUTICS: COMPANY SNAPSHOT
- TABLE 89. HANUGEN THERAPUTICS: PRODUCT SEGMENTS
- TABLE 90. HANUGEN THERAPUTICS: PRODUCT PORTFOLIO
- TABLE 91. NMD PHRAMA A/S: KEY EXECUTIVES
- TABLE 92. NMD PHRAMA A/S: COMPANY SNAPSHOT
- TABLE 93. NMD PHRAMA A/S: PRODUCT SEGMENTS
- TABLE 94. NMD PHRAMA A/S: PRODUCT PORTFOLIO
- TABLE 95. NMD PHRAMA A/S: KEY STRATERGIES
- TABLE 96. NOVARTIS AG: KEY EXECUTIVES
- TABLE 97. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 98. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 99. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 100. NOVARTIS AG: KEY STRATERGIES
- TABLE 101. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 102. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
- TABLE 104. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 105. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
- TABLE 106. PFIZER INC.: KEY EXECUTIVES
- TABLE 107. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 108. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 109. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 110. SCHOLAR ROCK HOLDING CORPORATION: KEY EXECUTIVES
- TABLE 111. SCHOLAR ROCK HOLDING CORPORATION: COMPANY SNAPSHOT
- TABLE 112. SCHOLAR ROCK HOLDING CORPORATION: PRODUCT SEGMENTS
- TABLE 113. SCHOLAR ROCK HOLDING CORPORATION: PRODUCT PORTFOLIO
- TABLE 114. SCHOLAR ROCK HOLDING CORPORATION: KEY STRATERGIES
- TABLE 115. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: KEY EXECUTIVES
- TABLE 116. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT
- TABLE 117. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: PRODUCT SEGMENTS
- TABLE 118. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: PRODUCT PORTFOLIO
- TABLE 119. BEIJING JINLAN GENE TECHNOLOGY CO., LTD.: KEY STRATERGIES
- TABLE 120. IONIS PHARMACEUTICALS, INC.: KEY EXECUTIVES
- TABLE 121. IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 122. IONIS PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
- TABLE 123. IONIS PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 124. IONIS PHARMACEUTICALS, INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN SPINAL MUSCULAR ATROPHY TREATMENT MARKET (2023-2032)
- FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 06. MODERATE THREAT OF SUBSTITUTES
- FIGURE 07. MODERATE INTENSITY OF RIVALRY
- FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALSPINAL MUSCULAR ATROPHY TREATMENT MARKET
- FIGURE 09. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY TYPE, 2022(%)
- FIGURE 10. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 1, BY COUNTRY 2022 AND 2032(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR TYPE 2, BY COUNTRY 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, BY END USER, 2022(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF SPINAL MUSCULAR ATROPHY TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 19. SPINAL MUSCULAR ATROPHY TREATMENT MARKET BY REGION, 2022
- FIGURE 20. U.S. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 21. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 22. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 23. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 24. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 25. UK SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 26. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 27. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 28. REST OF EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 29. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 30. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 31. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 32. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 33. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 34. REST OF ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 35. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 36. MIDDLE EAST AND AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET, 2022-2032 ($MILLION)
- FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 41. COMPETITIVE DASHBOARD
- FIGURE 42. COMPETITIVE HEATMAP: SPINAL MUSCULAR ATROPHY TREATMENT MARKET
- FIGURE 43. TOP PLAYER POSITIONING, 2022
- FIGURE 44. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 45. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 46. CYTOKINETICS: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 47. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 48. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 49. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 50. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
- FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 53. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 54. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 55. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 56. SCHOLAR ROCK HOLDING CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 57. IONIS PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
